M&A Deal Summary

Curium Pharma Acquires Eczacıbaşı-Monrol

On April 8, 2024, Curium Pharma acquired life science company Eczacıbaşı-Monrol

Acquisition Highlights
  • This is Curium Pharma’s 2nd transaction in the Life Science sector.
  • This is Curium Pharma’s 1st transaction in Turkey.

M&A Deal Summary
Date 2024-04-08
Target Eczacıbaşı-Monrol
Sector Life Science
Buyer(s) Curium Pharma
Deal Type Add-on Acquisition

Target

Eczacıbaşı-Monrol

Istanbul, Turkey
Eczacıbaşı-Monrol is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine. Eczacıbaşı-Monrol is based in Istanbul, Turkey.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Curium Pharma

Paris, France
Category Company
Founded 2017
Sector Life Science
DESCRIPTION

Curium Pharma is the largest nuclear medicine company with more than a century of industry experience. Curium develops, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Curium Pharma was founded in 2017 and is based in Paris, France.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
Country (Turkey) 1 of 1
Year (2024) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-12-02 MAP Medical Technologies Oy

Tikkakoski, Finland

MAP Medical Technologies Oy is focused on developing and manufacturing radiopharmaceuticals. MAP Medical Technologies is based in Tikkakoski, Finland.

Buy -
Mergr

Product

Company

Legal